Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.68 -3.27 (-1.22%) Market Cap: 34.27 Bil Enterprise Value: 33.19 Bil PE Ratio: 0 PB Ratio: 1,062.72 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 01, 2021 / 07:40PM GMT
Release Date Price: $148.75 (+0.44%)
Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Hi, everyone. Welcome to the Cowen Healthcare Conference fireside chat with Alnylam. I'm covering analyst, Ritu Baral. And with us today is CEO, John Maraganore, who I'm sure most of you, if not all of you, already know.

Thanks, John, for joining us today.

Questions & Answers

Ritu Subhalaksmi Baral
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

I guess we -- let's kick it off. I think most of the folks who've dialed in don't necessarily need to level set. You've already reported the quarter. You did really well for -- I mean, let's just start there.

ONPATTRO is doing really surprisingly well for every 3-week IV drug during COVID when people don't really want to go out or go into infusion centers, et cetera. What do you believe -- what does your marketing team believe is driving this? And is this -- we're a couple of years out from launch at this point. Is this sustained? Like is this despite

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot